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Objectives: The use of stem cell therapy for the repair of cartilage defects has shown promising results in
in vitro and animal studies. However, only a small number of studies have been performed to evaluate the
beneﬁts in human subjects. The aim of this study is to systematically review studies that focus on the
clinical application of stem cell therapy to treat cartilage defects in human subjects.
Design: A literature search was performed, adhering to the PRISMA guidelines, to review any studies
using such techniques in humans. Our initial search retrieved 105 articles listed on MEDLINE, EMBASE,
Google Scholar, CINHal and SPortDiscus. From these studies, 11 studies meeting the eligibility criteria
were selected and formed the basis of our systematic review.
Results: There is limited evidence showing the beneﬁt in humans. The study designs, follow-up methods
and criteria reporting and evaluation vary greatly between the studies and are outlined in our systematic
review.
Conclusion: With an increasing body of evidence in non-human and in vitro studies, more human trials
are required. More high level studies with extensive and robust validated reporting methods should be
conducted to evaluate the true effect of such techniques in human cartilage defect repairs.
 2013 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Tissue is frequently damaged or lost in injury and disease of the
musculoskeletal system. Advances in trauma and orthopaedic
surgery have been highly successful in repairing, realigning,
reconstructing and replacing damaged musculoskeletal structures.
Tissue engineering is the science of generating replacement tissue
for clinical use employing molecular and cellular techniques,
combined with material engineering principles. This may involve
the use of cells alone or withmatrices. There has been an increasing
interest in tissue engineering approaches such as stem cell appli-
cations in surgical practice to deal with damaged or lost tissue.
Although there have been developments in the use of tissue engi-
neering in almost all surgical disciplines, particularly signiﬁcant
advances are being made in orthopaedics, especially in cartilage
repair1.W. Khan, University College
tal Sciences, Royal National
dom. Tel: 44-7791-025554.
astides), mukai.cg@mac.com
k (N. Maffulli), wasimkhan@
s Research Society International. PCartilage defects are often disabling and affect young, active
patients. In many cases, normal function is not regained after
treatment, and joint arthroplasty may not be a satisfactory option2.
Techniques such as subchondral drilling, abrasion andmicrofracture
result in the formation of ﬁbrocartilage within the defect. Newer
techniques such as autologous osteochondral transplantation and
autologous chondrocyte implantation (ACI) have been developed3.
The use of stem cell therapy is an exciting alternative strategy that
aims to form hyaline cartilage within the defect. This newly formed
hyaline like cartilage would integrate with the surrounding normal
cartilage and be mechanically functional4.
Numerous in vivo animal studies show the potential beneﬁts of
using stem cells to treat musculoskeletal diseases. However, given
the complexity of the treatment and the potential ethical and
economic considerations, only a few have been translated into
human clinical studies2.
The aim of this article is to review studies that focus on the
clinical application of stem cell therapy to treat cartilage defects in
skeletally mature human subjects.
Methods
This review was undertaken in accordance with the PRISMA
guidelines.ublished by Elsevier Ltd. All rights reserved.
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across several databases (MEDLINE, EMBASE, Google Scholar,
CINHal and SPortDiscus), from 1950 to present. Keywords used in
the selection were “(“stem cells”[MeSH Terms] OR (“stem”[All
Fields] AND “cells”[All Fields]) OR “stem cells”[All Fields]) AND
(“cartilage”[MeSH Terms] OR “cartilage”[All Fields]) AND (“wound
healing”[MeSH Terms] OR (“wound”[All Fields] AND “healing”[All
Fields]) OR “wound healing”[All Fields] OR “repair”[All Fields]) AND
vivo[All Fields]”.
All articles not in English were excluded. The study selection
process involved screening the study titles to check their relevance
to the subject. The abstracts and included articles were subse-
quently reviewed by two of the authors (PP and WSK) indepen-
dently to check the primary goal and outcome measures of each
included study. Eligible studies had to report outcomes regarding
function or pain scores, and have a reasonable follow-up period. All
journals were considered, and all relevant articles were retrieved. A
hand search for studies meeting the inclusion criteria was per-
formed on the reference lists of included studies and relevant re-
view articles. Articles that described surgical techniques without
patient follow-up, commentaries or review articles were also
excluded.Results
The results retrieved 105 articles listed on MEDLINE, EMBASE,
Google Scholar, CINHal and SPortDiscus. The selection process is
shown in a ﬂow diagram in Fig. 1. One article was a review of all of
the patients treated by the same research team and was thusStudies retrieved as potentially relevant
Studies excluded 
due to lack of in
vivo human 
participants = 93
Studies retrieved for more detailed
evaluation = 12
Study excluded as 
it was a collective 
review of individual 
studies already 
included in this 
review = 1
Appropriate studies retrieved and included 
in this systematic review = 11
and screened for retrieval = 105
Fig. 1. The selection process for the studies included in this systematic review is shown
in a ﬂow diagram.excluded5. Following this process, the resulting 11 articles formed
the basis of our review6e16. The details of the included studies are
summarised in Tables I and II.
Of the included studies, there was no randomised controlled
trial. The other studies were prospective case series, cohort and
case control studies, and case reports. Therewere three studies that
included patients not treated with Mesenchymal Stem Cells
(MSCs); a cohort study compared ACI with MSC implantation8, a
case control study evaluated patients undergoing a high tibial
osteotomy alone or in combination with MSC implantation12, and
lastly a prospective cohort study comparing open ACI procedures,
arthroscopic ACI procedures and arthroscopic implantation of bone
marrow derived cells14. Although the data for all study groups is
presented in Tables I and II, only the MSC group was included in
further analyses.
Two studies by the same research group with 73 patients used
cartilage defects arising from the talardome in the ankle joint13,14. All
of these lesions were deﬁned as grade II lesions. The remaining nine
studies with 96 patients investigated defects in the knee joint. These
lesions were deﬁned as grade III or grade IV in 82 patients. Two
studies9,12 with 14 patients did not specify the grade of the lesion. Of
the knee lesions in the 96 patients, 59 involved the femoral condyles,
23 involved the patella, 10 involved the trochlea, 13 were multiple
and twowere not speciﬁed.Out of the 59 femoral condylar lesions 35
were located at themedial condyle,10 at the lateral condyle and two
at both condyles. The location of 12 femoral condylar lesionswas not
speciﬁed. Of the 23 patellar lesions, three were multiple.
The number of patients undergoing additional procedures in the
knee joint was 52. Twenty-ﬁve patients underwent a high tibial
osteotomy, seven patients underwent partial meniscectomy, 10
underwent anterior cruciate ligament (ACL) reconstruction, seven
underwent patella realignment surgery, one patient had a lateral
release, one patient had a meniscal repair, and one had an osteo-
phyte removed. A calcaneal osteotomy was the only one additional
ankle procedure14 in the 73 ankle patients.
The two studies involving the ankle joint13,14 and one study
involving the knees of 20 patients14 isolated bone marrow derived
MSCs from the posterior iliac crest, whereas all other studies used
the anterior iliac crest. The implantation timing and methods also
varied. The three studies using the posterior iliac crest harvest
implanted the bonemarrow derived cells immediately whereas the
other studies culture expanded the MSCs in vitro and performed a
second-stage implantation procedure at a later date. The MSCs
were expanded in culture for 3e4 weeks in most cases; for seven
patients involved in two studies6,7 the duration is not speciﬁed.
Collagen was the most commonly used scaffold and was used with
a periosteal ﬂap in 54 patients and with platelet rich ﬁbrin in 23
patients. Hyaluronic acid was used with platelet rich ﬁbrin in 45
patients. In one study14 involving 25 patients either a collagen or
hyaluronic acid scaffold was used, but not speciﬁed. A platelet rich
ﬁbrin scaffold with a periosteal ﬂap was used for ﬁve patients.7 One
study involving two patients did not specify the scaffold used9.
In terms of outcome measurements and post-implantation
evaluation of cartilage regeneration, there were marked differ-
ences. Most studies utilised one or more validated objective and
subjective scoring systems such as the American Orthopaedic Foot
and Ankle Society (AOFAS) score, Lysholm score, Knee injury and
Osteoarthritis Outcome Score (KOOS), International Knee Docu-
mentation Committee (IKDC) score and the Revised Hospital for
Special Surgery Knee (RHSSK) score. Only two studies used a vali-
dated scoring system to assess the appearance of the actual
transplanted cartilage; Haleem et al.7 used the International
Cartilage Repair Society (ICRS) arthroscopy score and Buda et al.15
used the Magnetic resonance Observation of CArtilage Repair Tis-
sue (MOCART) score. In addition, a number of studies used other
Table I
Summary table showing the study type, location and size of defects, number of patients, their ages, grade of osteoarthritis (OA), associated procedures, harvest site and techniques used for the included studies
Authors Study type Location Size Number
of patients
Age Grade OA Associated operations Harvest site,
technique
Implantation technique
Kasemkijwattana
et al., 20116
Prospective case series Two lateral femoral
condyles
2.2 and 2.5 cm2 2 Not speciﬁed III/IV Two ACL
reconstructions
Anterior iliac crest
using LA
Cells expanded for
unspeciﬁed duration.
Implanted with a
collagen scaffold and
periosteal ﬂap coverage
Haleem
et al., 20107
Prospective case series Three lateral femoral
condyles, two medial
femoral condyles
Mean 5.8 cm2
(3e12 cm2)
5 Mean 25.4
years (range
21e37 years)
III/IV One ACL
reconstruction
Anterior iliac crest
using LA
Cells expanded for
unspeciﬁed duration.
Implanted with
platelet rich ﬁbrin glue
and periosteal ﬂap
coverage
Nejadnik
et al., 20108
Cohort study comparing
ACI and stem cells with
36 patients in each group
(data for only the stem
cell group shown)
13 patella, 14 trochlea,
12 femoral condyle and
seven multiple lesions
Mean 4.6 cm2 36 Mean 44.0
years (SD 11.4
years)
III/IV Five patella
realignments,
ﬁve HTOs, one ACL
reconstruction, one
meniscectomy
Anterior iliac crest
using LA
Four-week expansion
of cells followed by
implantation using a
collagen scaffold and
periosteal ﬂap
Matsumoto
et al., 20109
Prospective case series Knee e site not speciﬁed Not speciﬁed 2 Not speciﬁed Not
speciﬁed
None Anterior iliac crest
using LA
Cell expansion for
3 weeks
Wakitani
et al., 200710
Prospective case series Nine patella 1.7 cm2
(1.0e4.2 cm2)
3 (nine
lesions)
Mean 40 years
(range 31e45
years)
III/IV None Anterior iliac crest
using LA
Cell expansion for
3 weeks. Implantation
with collagen scaffold
and periosteal ﬂap
Kuroda
et al., 200711
Case report Medial femoral condyles 2  3 cm 1 31 years IV None Anterior iliac crest
using LA
Cell expansion for 3
weeks. Implantation
with collagen scaffold
and periosteal ﬂap
Wakitani
et al., 200812
Case control study
comparing HTO with
and without stem cells
with 12 patients in each
group (data for only the
HTO with stem cell group
shown)
Medial femoral condyles Mean
14  35 mm
12 63 years
(range 49e70
years)
Not
stated
HTO in all 12
patients
Anterior iliac crest
using LA
Cell expansion for 3
weeks. Implantation
with collagen scaffold
and periosteal ﬂap
Giannini
et al., 200913
Prospective case series Talar dome Mean size
2.07  0.48 cm2,
mean depth
4.0  0.9 mm
48 Mean 28.5
years (range
19e38 years)
Grade II None Posterior iliac crest
using GA or LA
Immediate implantation
of cells using a collagen
(23 patients) or hyaluronic
acid (25 patients) scaffold
Giannini
et al. 201014
Prospective cohort study
comparing open ACI (10
patients), arthroscopic
ACI (46 patients), and
arthroscopic expanded
stem cell implantation
(25 patients). Data for
only the stem cell group
shown
Talar dome Mean depth
4.0  0.9 mm,
mean size
2.18  0.5 cm2
25 Mean 28.2 
9.4 years
Grade II One calcaneal
osteotomy
Posterior iliac crest
using GA or LA
Immediate implantation
of cells using a collagen
powder scaffold or
hyaluronic acid membrane
loaded with bone marrow
concentrate and platelet
rich ﬁbrin gel
Buda
et al., 201015
Prospective case series 14 Medial femoral condyles
Four Lateral femoral condyles
Two both femoral condyles
Not speciﬁed 20 15e50 years Grade
III/IV
Six partial
meniscectomies
One meniscal repair
Two ACL reconstructions
Three HTO
One osteophyte removal
Posterior iliac
crest using GA or LA
Immediate implantation
of cells using a hyaluronic
acid membrane and platelet
rich ﬁbrin gel
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Objective and subjective scoring system results showed statistically
signiﬁcant improvements following stem cell treatment of cartilage
defects as shown in Table II.
Two studies8,10 involving 34 patients only looked at outcome
scores and did not perform any additional evaluations. Of the 135
patients from 10 studies where evaluation measures other than
outcome scores were used, 93 patients10,13e15 only had anMRI scan,
two patients6 had only an arthroscopy and nine patients7 had both
an MRI and arthroscopy. In all of these patients there was radio-
logical and/or arthroscopic evidence of full integration of the lesion.
A further 34 patients were investigated with an arthroscopy and a
biopsy of the implantation site, 15 of whom also had an MRI. Of
these, 318,13e16 were histologically reported as ‘hyaline’ or ‘hyaline-
like’, while the remaining three9,10 were reported as ‘ﬁbrocartilage’.
The quality of the included studies was assessed using the
Coleman Methodology Score (CMS), that assesses methodology
using 10 criteria, giving a total score between 0 and 100 as shown in
Table III. A score of 100 indicates that the study largely avoids
chance, various biases and confounding factors. Table IV summa-
rises the scores for each individual study with the lowest scores for
a studies being 2511, and the highest score being 408. The remaining
seven studies scored between 30 and 39. The average score was 34
[standard deviation (SD)¼ 6] and only two scoring 2511 and 408 fell
outside 1 SD. The study by Kuroda et al.11 scored 25. It is a case
report of one patient undergoing stem cell implantation with
collagen scaffold and a periosteal ﬂap for a type IV 2  3 cmmedial
femoral condylar defect. The follow-up period is limited to
7 months and the study failed to use any objective outcome scores
or imaging. Arthroscopic and histological evaluations were how-
ever performed and showed hyaline like cartilage. The highest CMS
was achieved by a study by Nejadnik et al.8 that scored 40. It is a
cohort study comparing ACI and stem cells with 36 patients in each
group. The chondral defects in the stem cell group were grade III or
IV and located in the patella (13), trochlea (14), femoral condyle
(12) or at multiple lesions (7) with a mean size of 4.6 cm2. Cells
were expanded and implanted using a collagen scaffold and peri-
osteal ﬂap. A number of additional procedures were performed in
the stem cell group including patella realignments (5), high tibial
osteotomies (5), ACL reconstruction (1), and meniscectomy (1). The
patients were followed up at 3, 6, 9, 12, 18 and 24 months and
completed SF 36 Questionnaires, and had IKDC, Tegner Activity and
Lysholm scores measured. Three patients underwent arthroscopy
and biopsies showing hyaline like cartilage. The study by Giannini
et al.13 scored 39, and was the second highest score. It is a pro-
spective case series of 48 patients with a mean age of 28.5 years
(range 19e38 years) with grade II talar dome cartilage defects
(mean size 2.07 0.48 cm2, mean depth 4.0 0.9 mm). All patients
underwent immediate implantation of bone marrow derived cells
from the posterior iliac crest under general anaesthetic (GA) using
either a collagen or hyaluronic acid scaffold. All patients were
evaluated pre and post-operatively with AOFAS scores as well as
MRI scans. In addition, ﬁve patients also had a biopsy at 12 months
time showing hyaline cartilage like tissue.
Discussion
The ‘holy grail’ in the management of osteoarthritis and carti-
lage loss, especially in the initial stages is to repair the affected area
and thus halt the progression of the damage. Arthroplasty for se-
vere disease or for older individuals is a well recognised and suc-
cessful treatment option.
ACI procedures have shown promising results in the short to
medium term17,18. However a recent meta-analysis of several
leading databases showed that although the clinical outcomes
Table II
Summary table showing the follow-up, outcome measures, pre-operative and post-operative scores, post-operative rehabilitation, and evaluation method
Authors Follow-up Pre-operative scores Post-operative scores Post-operative
rehabilitation
Evaluation
Kasemkijwattana
et al., 20116
31M KOOS Symp:89 Pain:92
ADL:62 Sports:75 QOL:75
IKDC 21
KOOS Symp:89 Pain:92
ADL:62 Sports:75 QOL:75
IKDC 74 (P < 0.05)
NWB for 2 weeks,
restrict running
till 9 months
Arthroscopy showing full
integration
KOOS Symp:36 Pain:36
ADL:32 Sports:20 QOL:31
IKDC 37
KOOS Symp:100 Pain:100
ADL:100 Sports:100 QOL:94
IKDC 94 (P < 0.05)
Haleem et al., 20107 14.2M
(12e16M).
All had F/U
at 6M
and 12M
Lysholm 20,
RHSSK 31
Lysholm 6M: 76, 12M: 76 (P < 0.05)
RHSSK 6M: 69, 12M: 69 (P < 0.05)
PWB at 4e6 weeks,
FWB at 8 weeks
Arthroscopy and MRI at
6M and 12M showing
ﬁlled defectsLysholm 45
RHSSK 47
Lysholm 6M: 66, 12M: 76 (P < 0.05)
RHSSK 6M: 75, 12M: 79 (P < 0.05)
ICRS arthroscopy score 12M: 8
Lysholm 53
RHSSK 71
Lysholm 6M: 95, 12M: 95 (P < 0.05)
RHSSK 6M: 90, 12M: 90 (P < 0.05)
Lysholm 50
RHSSK 62
Lysholm 6M: 92, 12M: 92 (P < 0.05)
RHSSK 6M: 93, 12M: 93 (P < 0.05)
ICRS arthroscopy score 12M: 12
Lysholm 38
RHSSK 58
Lysholm 6M: 79, 12M: 91 (P < 0.05)
RHSSK 6M: 68, 12M: 88 (P < 0.05)
Nejadnik et al., 20108
(only results for
stem cell group
shown)
3, 6, 9, 12, 18
and 24M
Not speciﬁed SF 36 Questionnaire
Physical role functioning
signiﬁcantly better in stem cell
group. No other signiﬁcant differences
IKDC, Tegner Activity and Lysholm scores
No signiﬁcant differences between groups.
Men did signiﬁcantly better than
women in both groups in all the
above scoring systems
PWB for 6 weeks Three arthroscopies and
biopsies showing hyaline
like cartilage
Matsumoto et al., 20109 11 years
(10 and
12 years)
Pain whilst mobilising Both remain symptom free Not speciﬁed Arthroscopy and biopsy
at 2 years showing
ﬁbrocartilage
Wakitani et al., 200710 18.6M
(18e20M)
R Pat IKDC: 63L Pat
IKDC: 48
R Pat IKDC: 54L Pat: 75 at 7M
R Pat IKDC: 63L Pat: 79 at 18M
FWB at 3 weeks Arthroscopy and biopsy
showing ﬁbrocartilage
R Pat IKDC: 30L Pat
IKDC: 11
R Pat IKDC: 74L Knee Pat: 67 at 7M
Same scores at 20M
MRI at 12M showing
complete coverage of
defects
R Pat IKDC: 64 R Pat IKDC: 77 at 6M
Same scores at 18M
Kuroda et al., 200711 7M Pain following sporting
injury.
Knee range of motion
limited
in extension
Returned to pre-injury level
activities and was pain free
Arthroscopy and biopsy
showing hyaline like
cartilage
Wakitani et al., 200812 16M Not speciﬁed Histological and arthroscopic
scores better in MSC group (speciﬁc
scoring system or scores not speciﬁed)
Not speciﬁed Not speciﬁed
64M Not speciﬁed Clinical scores not signiﬁcantly better
between the two groups
(speciﬁc scoring system or scores
not speciﬁed)
Giannini et al., 200913 24M All patients AOFAS scores
Pre-op: 64.4
All patients AOFAS scores
6M: 83.3 12M: 88.9 18M: 89.7 24M: 91.4
(all P < 0.0005)
Five patients with
collagen scaffolds
hadbiopsy at 12M
showing hyaline
cartilage like tissue.
MRI at 24M showed
newly formed tissue
in all patients
A further MRI analysis
was carried out at 24M
and is described in the
‘Discussion’ section of
this paper
Collagen powder scaffold
AOFAS scores
Pre-op: 62.5
Collagen powder scaffold AOFAS scores
6M: 82.3 12M: 86.9 18M: 87.2 24M: 89.8
(all P < 0.0005)
Hyaluronic acid membrane
scaffold AOFAS scores
Pre-op: 66.2
Hyaluronic acid membrane scaffold
AOFAS scores
6M: 82.3 12M: 90.7 18M: 92.0 24M: 92.8
(all P < 0.0005)
Giannini et al., 201014
(Only results for the
stem cell group
presented)
36M AOFAS scores
65  16
Arthrosc ACI þ BMDSC AOFAS scores
12M: 89  9 (P < 0.0005) 36M: 93  8
(P < 0.0005)
P < 0.0005 between 12M vs 36M
Cast 2 weeks for open
No WB for 6 weeks
PWB 2e4 weeks
Five patients biopsied
at 12M showing hyaline
like tissue
Buda et al., 201015 24M IKDC score 32.9  14.2
KOOS 47.1  14.9
IKDC score 90.4  9.2 at 29.0  4.1
months (P < 0.005)
KOOS score 93.3  6.8 at 29.0  4.1
months (P < 0.005)
MOCART score 24M
No WB for 6 weeks
PWB 2e4 weeks
Two patients biopsied
at 12M showing type
II collagen cartilage
(hyaline cartilage)
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Table II (continued )
Authors Follow-up Pre-operative scores Post-operative scores Post-operative
rehabilitation
Evaluation
Defect repair: 14 complete, four
hypertrophy, two incomplete
Integration: 16 complete, two incomplete,
two visible defect
Surface tissue: 14 intact, six damaged
Structure: six homogeneous, 14
inhomogeneous Subchondral lamina:
six intact, 14 not intact
Subchondral bone: six intact, 14 not intact
Gobbi et al., 201116 2 years
minimum
6, 12, 24M
Tegner 2
KOOS Symp:65 Pain:67
ADL:70 Sports:45 QOL:40
6M
Tegner 3
KOOS Symp:85 Pain:90 ADL:90
Sports:40 QOL:65
12M
Tegner 4
KOOS Symp:90 Pain:90 ADL:90
Sports:75 QOL:80
24M
Tegner 4
KOOS Symp:95 Pain:95 ADL:95
Sports:75 QOL:80
Rehabilitation
goal driven
rather than time
frame derived
Four arthroscopies at
mean 13.5M post-op all
intact and stable
Three biopsies: hyaline
like tissue
MRI at 24M: complete
ﬁlling 12/15. Integration
14/15
ICRS ¼ International Cartilage Repair Society arthroscopy score; BMDSC ¼ bone marrow derived stem cells; NWB ¼ non-weight bearing; PWB ¼ partial weight bearing.
Table III
Coleman methodology scoring system applied to each included study. Maximum
score of 100
Part A: Only one score to be given for each six sections
1 Study size:
Number of
procedures
<30 0
30e50 4
51e100 7
>100 10
2 Mean follow-up
(months)
<12 0
12e36 4
37e60 7
>61 10
3 Surgical approach Different approach used and
outcome not reported separately
0
Different approaches used and
outcome separately reported
7
Single approach used 10
4 Type of study Case series (level IV) 0
Retrospective control trial (level III) 5
Case control study (level III) 5
Prospective comparative study (level II) 10
Randomised control study (level I) 20
5 Descriptions of
surgical techniques
Inadequate (not stated, unclear) 0
Fair (technique only stated) 5
Adequate (technique and details
procedure given)
10
6 Description of
post-operative
rehabilitation
Described 5
Not described 0
Part B: Scores may be given for each option in each of the three sections if
applicable
1 Outcome criteria Outcome measures clearly deﬁned 2
Timing of outcome assessment stated 2
Use of outcome criteria reliably stated 3
General health measure included 3
2 Procedure of
assessing outcomes
Subjects recruited 5
Investigator independent of surgeon 4
Written assessment 3
Completion of assessment by
patients themselves with minimal
investigator assistance
3
3 Description of
subject selection
process
Selection criteria reported and unbiased 5
Recruitment rate >90% 5
Recruitment rate <90% 0
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lack of large high level evidence studies or comparable outcome
measures between studies failed to show a signiﬁcant advantage or
disadvantage of this technique compared to other techniques such
as osteochondral transplantation or microfracture19.
Cells used in tissue engineering could be autologous, allogeneic
or xenogeneic. The cells could be stem cells or cells further down
the differentiation pathway. Stem cells possess self-renewal ca-
pacity, and exhibit long-term viability and multilineage differenti-
ation potential. Ethical, political and religious issues surround the
use of embryonic stem cells. In contrast, the use of autologous adult
stem cells is generally well accepted. Stem cells have been identi-
ﬁed in a number of adult tissues, albeit in small numbers. In
addition to bone marrow, MSCs have been identiﬁed in other tis-
sues including adipose tissue and fat pad from which MSCs are
generally isolated and subsequently expanded in culture1. These
cells are characterised or deﬁned using a set of cell surface markers
and can then be differentiated along a given differentiation
pathway, e.g., osteoblast or chondrocyte, using predeﬁned culture
conditions before being used for clinical applications20,21.
MSCs are less tumorigenic than their embryonic counterparts22,
and provide an autologous source of cells eliminating concerns
regarding rejection and disease transmission. There is also evidence
to suggest that MSCs have immunosuppressive potential as co-
culture with MSCs inhibits T-cell lymphocyte proliferation23, and
MSCs have also been shown to be negative for majorTable IV
CMSs for each included study
Part A Part B Total
1 2 3 4 5 6 1 2 3
Kasemkijwattana
et al., 20116
0 4 10 0 10 5 3 3 0 35
Haleem et al., 20107 0 4 10 0 10 5 3 5 0 37
Nejadnik et al., 20108 4 4 10 10 10 5 3 5 0 40
Matsumoto et al., 20109 0 10 10 0 5 0 2 3 0 30
Wakitani et al., 200710 0 4 10 0 10 5 3 3 0 35
Kuroda et al., 200711 0 0 10 0 10 0 2 3 0 25
Wakitani et al., 200812 0 2 10 4 10 0 2 3 0 31
Giannini et al., 200913 4 4 10 0 10 5 3 3 0 39
Giannini et al. 201014 0 4 10 10 10 5 3 5 0 37
Buda et al., 201015 0 4 10 0 10 5 3 3 0 35
Gobbi et al., 201116 0 4 10 0 10 5 3 3 0 35
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stimulatory molecules B7-1 and B7-224,25.
Animal and in vitro studies have shown that there is a place for
the use of stem cells in the management of musculoskeletal con-
ditions26. Based on the success reported on such studies, there is
clear evidence that over the last few years the appeal to translate
this potential beneﬁt to human subjects is growing.
As evident from the CMS, there was a wide difference in
methodology scores. The studies included in this review are not
homogeneous and vary between each other in both study design
and outcome measurements. Seven of these studies are case re-
ports or series, one is a case control, one is a cohort study, and only
two are randomised controlled trials.
With a total of 81 patients, Giannini et al.14 allocated patients to
one of three treatment options; open ACI vs arthroscopic ACI vs
arthroscopic bone marrow derived cells transplantation. The bone
marrow derived cells were harvested from the posterior iliac crest
with no adverse reactions. Of the three groups, the pre-operative
AOFAS score was signiﬁcantly lower in those patients allocated to
open ACI treatment; 38, 57 and 65 for each treatment group
respectively. In all cases, 12 and 36 months post-treatment AOFAS
scores were signiﬁcantly better and similar in all groups. At imag-
ing, integration of the cartilage was apparent in 76% of patients
who underwent open ACI. Patients allocated to the other two
groups did not have any imaging conﬁrmation of integration, but
the biopsy at the implantation site at 12 months in four or ﬁve
patients from each group conﬁrmed the presence of a hyaline like
tissue.
In the only case control study included in this review, Wakitani
et al.12 allocated two groups of 12 patients to either a high tibial
osteotomy or a high tibial osteotomy with the application of MSCs.
The authors did not give objective details of post-operative recov-
ery or rehabilitation regimens. They did however comment that
histological, visual (via arthroscopy) and patient reported outcomes
(the scoring system used was not commented on) were better in
the group treated with the addition of MSCs.
Despite the discrepancy in methodology and outcome mea-
surements, the summary table provided reveals several similarities.
Outcomes in all studies were highly satisfactory and promising.
Harvesting of the stem cells was undertaken in a similar fashion
from the iliac crest with no reported complications.
When formal outcomemeasures were administered, there were
statistically signiﬁcant improvements. Kasemkijwattan et al. re-
ported signiﬁcant improvements in their case series with the Knee
injury and Osteoarthritis Outcome Score (KOOS) and the IKDC
score6. This was further supported by arthroscopy conﬁrming full
integration of what appeared to be a cartilage-like lesionwithin the
treated defect. No biopsy was undertaken. Haleem et al.7 conﬁrmed
improvements using Lysholm and RHSSK scores in a series of ﬁve
patients at six at 12 months. Additionally, two of ﬁve patients
consented to arthroscopy, and both had nearly normal Interna-
tional Cartilage Repair Society (ICRS) arthroscopic scores at
12 months. Nejadnik et al.8 reported improvement in patient SF 36
Questionnaire results pre- and post-treatment, but no signiﬁcant
improvements in IKDC, Lysholm and Tegner Activity scores. Buda
et al.15 undertook a detailed prospective follow-up for their case
series of 20 osteochondral defects. They reported signiﬁcant im-
provements in IKDC and KOOS scores at 2 years post-application of
MSC patches to the defects. This is one of only two studies included
in this review to assess the results using the MOCART scoring
system. At 2 years post-procedure, they noted that 14 of 20 defects
had been repaired, and 16 lesions had undergone complete inte-
gration with the surrounding cartilage. However, only six lesions
were homogenous in structure and presented intact with sub-
chondral lamina and bone. Of the 20 samples, two had anarthroscopic biopsy and histological examination at 1 year, which
conﬁrmed type II cartilage formation.
Battaglia et al.27 undertook a qualitative MRI study to evaluate
the efﬁcacy of bone marrow derived cell transplantation to repair
osteochondral lesions. They aimed to investigate the validity of MRI
T2-mapping sequence in characterising the reparative tissue ob-
tained and its ability to correlate with clinical results. They used a
cohort group of 20 patients, recruited from a study included in this
paper13, who underwent treatment for talar dome osetochondral
lesions. They were compared to a matched group of 20 healthy
volunteers. MRI results evaluated by MOCART scores showed that
the defect ﬁlling was complete in nine patients (45%), hypertrophic
in a further nine patients (45%), and incomplete with less than 50%
defect repair in two patients (10%). Integration to border zone was
complete in 13 patients (65%), the surface of repair tissuewas intact
in eight patients (40%), and the reparative tissue was isointense in
14 patients (70%). A regenerated tissuewith amean T2map value of
35e45 ms was considered compatible with the normal hyaline
cartilage and was found in all the cases, covering a mean percent-
age of 78% of the repaired lesion area. A tissue with T2 map value
<35 ms was considered expression of a ﬁbrocartilaginous regen-
erative tissue. It was found in limited foci (<10% of the repaired
site) in 13 patients (65%), and in up to 50% of the repaired lesion
area in one patient (5%).
MOCART scores were then compared with clinical outcome
scores (AOFAS). Patients with a repaired tissue’s signal that was
isointense with respect to normal hyaline cartilage (14 cases) had a
median AOFAS score of 100, while patients with a comparative
moderate signal hyperintensity with respect to normal hyaline
cartilage (six cases) obtained a mean score of 89. Comparing the T2
mapping with the clinical scores, they found a statistically signiﬁ-
cant (P ¼ 0.05) relationship between the clinical score and the
percentage of the lesion area repaired by tissue with a signal
compatible with hyaline cartilage.
Comparative studies such as those by Giannini et al.13 and
Nejadnik et al.8 showed signiﬁcantly improved outcomes for
patients who either underwent ACI or stem cell techniques, high-
lighting that there may be a role for both of these treatment regi-
mens. Although three of the included studies had two or fewer
subjects, they all reported good patient outcome scores and add to
the growing body of evidence supporting the use of stem cells in
the treatment of osteochondral defects.Limitations of current evidence
Several limitations are evident in the studies included in the
present review. Several centres and authors seem to have been
involved in a number of these investigations, therefore potentially
introducing bias into the subject. There were also different ways of
assessing the results, which is reﬂected in the CMS for each trial
(Table III). The beneﬁt of using scaffolds is still unclear. There are
also differences in the methods of reporting outcome measures:
some trials used recognised functional scoring systems, supported
by imaging and histological scores.
Most of the studies involve additional procedures other than
those directly related to the repair of cartilage defects, such as ACL
reconstructions, meniscectomies and cheilectomies. Therefore it is
possible that the functional outcome results may be partially or
even completely attributed to these secondary procedures.
Post-operative rehabilitation regimens, when reported, vary
between individual studies. It appears that they generally involve a
period of immobilisation following the procedures. However, there
is no agreed consensus on details or duration of the weight bearing
status.
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clinical trial that is adequately powered, with patients followed up
for initially the medium-term and then the longer-term. It is also
important that the study when published has adequate details on
the surgical technique and clinical post-operative management
allowing others to replicate the process satisfactorily. There is an
ever-increasing number of outcome measures available and it
would be important for future studies to use validated, reliable and
responsive outcome measures that are not subject to bias. These
will need to be supplemented with further evaluations including
MRI scans, and arthroscopic and histological analyses in at least a
subgroup of patients.
Furthermore, other types of stem cells such as synovial and
adipocyte stem cells may also have a role to play in stem cell
therapies for cartilaginous joint defects, however these are beyond
the scope of this paper.
Conclusion
The success of stem cell treatment for osteochondral defects in
animals in vivo is well established. Currently there is a small body of
evidence showing that, if this technique is transferred into human
patients, the beneﬁts also appear to be translated. However, any
beneﬁt to human subjects still requires extensive evaluation. Tissue
engineering techniques in humans are still very much in its infancy.
Higher level of evidence studies are needed, with robust method-
ology and outcome measures so that any perceived beneﬁt can be
clearly evaluated and pursued further.
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